Following the expected close of the transaction, Teva’s generics business will be powered by one of the most formidable and well-equipped global operations networks in the industry. Planning for the combination of our two global generics networks is complex and requires significant coordination to ensure the combined generics business is appropriately structured to manufacture and distribute high quality products on Day 1 and going forward, without disruption.